3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Steve Latham of DonateStock, Arianne Dowdell of Houston Methodist, and Howard Berman of Coya Therapeutics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from fintech to health care DEI — recently making headlines in Houston innovation.

Steve Latham, co-founder and CEO of DonateStock

Houstonian and serial entrepreneur plans to scale nonprofit fintech toolThe sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

For the third time in his career, serial entrepreneur Steve Latham recession activity, so he feels confident he knows the playbook of how to handle what's on the horizon. For his latest venture, Donate Stock, a tech platform that simplifies stock donation for both the donor and the beneficiary, he's focused on weathering whatever storm is incoming.

"We've raised more money to extend our runway, and we're keeping a super tight lid on expenses because your cash is your oxygen," he says. "There are companies going out of business in our industry right now that had really promising businesses but just spent too much money before they could get to the revenue phase."

He shares the background story on DonateStock and his own career on last week's Houston Innovators Podcast episode. Read more and stream the episode.

Arianne Dowdell, vice president and chief diversity, equity and inclusion officer at Houston Methodist

Arianne Dowdell spoke with InnovationMap about Houston Methodist's DEI initiatives — and how they will help develop the hospital of the future. Photo courtesy of Houston Methodist

Innovation and equity are two things they have to go together — and Houston Methodist knows that. Which is why Arianne Dowdell serves as vice president and chief diversity, equity and inclusion officer at Houston Methodist. Under her leadership, the health care provider is putting the patients at the forefront of the hospital system's priorities through its DEI initiatives.

In an interview with InnovationMap, Dowdell shares more about these ongoing initiatives and her role, as well as the importance of DEI in innovative health care.

"It doesn't matter if you're down here in the medical center or out in Baytown," she says. "The innovation and what we're thinking about and the technologies and the way that we communicate with our patients, all that is part of innovation, which helps our DEI initiatives become more successful in everything that we're doing." Read more.

Howard Berman, CEO of Coya Therapeutics

A Houston biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has closed its IPO. Photo courtesy of Coya

A clinical-stage biotech company based in Houston has announced the closing of its $15.25 million IPO.

Coya Therapeutics, now trading under the ticker COYA, announced this week that its IPO — previously disclosed in December — has closed its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock, per a news release. Howard Berman, CEO of Coya Therapeutics, has lead the company since February of 2021. Read more.

The sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

Houstonian and serial entrepreneur plans to scale nonprofit fintech tool

Houston innovators podcast episode 167

Donating stock can be a smart way to offload assets and optimize a donation — but Steve Latham thought it was so cumbersome a process that it didn't even feel worth it.

"It was such a hassle that I never did it again," says Latham on the Houston Innovators Podcast.

That opportunity for innovation stuck with Latham as he advanced his career in AdTech in New York before moving back to Houston a few years ago. A serial entrepreneur, Latham was an early co-founder of the Houston Technology Center.

His latest venture is DonateStock — a tech platform that simplifies stock donation for both the donor and the beneficiary. The early version of Latham's vision was to clear up the lack of communication the original process had — nonprofits receiving stock donations were never notified about who made each donation.

The next phase for the fintech company, as Latham explains on the show, is to scale this idea by way of channel distribution, rather than just directly working between donor and nonprofit. He says he wants DonateStock to be a featured as an "easy button" option wherever donations are accepted online.

"Now that we've proven and shown that our process works," he says, "let's scale that to make that button available to the 20 or so online donation platforms."

In order to accomplish this goal, Latham is preparing to fundraise early this year, but it's a challenging time for fintech amid economic uncertainty, he says. So far, the company has raise $2.25 million from within the company's network along with angel and family office investment.

This is the third time in Latham's career that he's seen this recession activity, so he feels confident he knows the playbook of how to handle what's on the horizon.

Latham shares more about the difference his company is making within the nonprofit sector, as well as his passion for Houston and its local tech ecosystem — which he's seen grow up from afar — on the podcast episode. Stream the episode below, or wherever you listen to your podcasts.

Houston-based DonateStock is $50,000 richer after claiming a recent pitch competition win. Photo via donatestock.com

Houston fintech startup snags Capital Factory's $50,000 pitch investment prize

winner, winner

Capital Factory, one of the most active startup investors with a presence across Texas, recently hosted a virtual pitch competition — and one Houston startup took home the big prize.

As a part of the Houston Tech Rodeo, Capital Factory hosted its $50K Houston Investment Challenge with five finalists — DonateStock, Elastique, Elemental Coatings, M&S Biotics, and ScalaMed. The panel of judges included Andy Cloyd, vice president of Revolution; Aleece Hobson, venture partner at HX Venture Fund; and Juliana Garaizar launch director of Greentown Labs.

DonateStock, a tech-enabled tool that automates the stock donation process, took home the big win. Steve Latham, founder and chairman of DonateStock, presented the company's pitch and explained how the tool has the potential to unlock $100 billion for nonprofits.

"A lot of people aren't aware about the benefits of donating stock," Latham explains. "If you're sitting on stock that you've owned or several years that's appreciated quite a bit. If you sell it, you pay capital gains tax — anywhere from 15 to 30 percent. If you donate it, you avoid the tax and you get a big write off, you can deduct the full market value of the donated stock."

He goes on to explain how only 2 percent of people donate stock — and its due to the archaic process that it takes. DonateStock's platform optimizes the education of donors, the connection of nonprofits to new donors, and the simplification of the process. What used to take hours now takes just 10 minutes, Latham says.

Nonprofits get a free page, free customer support, and there is no fee to be on the platform, and DonateStock makes a 2 percent transaction fee. The company already has 40 nonprofits on the platform, and over 70 in the queue to sign up. The goal, Latham says, is to have 900 organizations online by the end of the year. He's already seen a lot of interest in light of the pandemic.

"This is the time to solve this problem," Latham says. "If you have friends at nonprofits or charities, you know what the pandemic did to giving programs. They've all been devastated and they have gotta find new ways to diversify and grow their revenue."

DonateStock anticipates a seed round later this year. It's the third startup Latham has worked on with his co-founder.

"We see a path to building a billion-dollar company over the next five years while impacting millions of lives around the world," he says.

Each of the other finalists' consolation prize is a connection and a foot in the door at Capital Factory, says CEO Joshua Baer.

"Every time we do one of these, we meet a bunch of companies that we end up working with — and many of whom we end up investing in," he says at the virtual event. "We're going to be following up with all of the companies from today. Anyone who was a finalist and up on the stage is someone we are excited about and interested in working more closely with."

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME